Table 2 Outcomes of Pregnant Women and Neonates Exposed to Sotrovimab (n = 22) for COVID-19 Treatment (Omicron Predominant Era)*
n (%) | ||
|---|---|---|
Median Infant Birth Weight (g) | 3220 | |
Median Gestational Age at Birth (weeks) | 38.9 | |
Premature labor | 2 (9) | |
Premature rupture of membranes | 2 (9) | |
Deaths | 0 (0) | |
Hospitalizations | 1 (5) | |
• Post-partum pyelonephritis | 1 (5) | |
ED Visit | 1 (5) | |
• Post-partum vaginal bleed | 1 (5) | |
Abortions | 0 (0) | |
Neurodevelopmental Defects | 0 (0) | |
Birth Defects | 1 (5) | |
• Prenatally diagnosed omphalocele (prior to sotrovimab) in mother with congenital defect history | 1 (5) |